These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 30995508)

  • 1. Cytokine Circuits in Cardiovascular Disease.
    Williams JW; Huang LH; Randolph GJ
    Immunity; 2019 Apr; 50(4):941-954. PubMed ID: 30995508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for cardiovascular disease.
    Lutgens E; Atzler D; Döring Y; Duchene J; Steffens S; Weber C
    Eur Heart J; 2019 Dec; 40(48):3937-3946. PubMed ID: 31121017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
    Grebe A; Hoss F; Latz E
    Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.
    Ji E; Lee S
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
    Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
    Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RP5-833A20.1/miR-382-5p/NFIA-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction.
    Hu YW; Zhao JY; Li SF; Huang JL; Qiu YR; Ma X; Wu SG; Chen ZP; Hu YR; Yang JY; Wang YC; Gao JJ; Sha YH; Zheng L; Wang Q
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):87-101. PubMed ID: 25265644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
    Ridker PM
    Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102
    [No Abstract]   [Full Text] [Related]  

  • 9. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
    Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
    Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches.
    Park KH; Park WJ
    J Korean Med Sci; 2015 Sep; 30(9):1213-25. PubMed ID: 26339159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-based immunotherapy targeting cytokines and atherothrombotic cardiovascular diseases.
    Ait-Oufella H; Libby P; Tedgui A
    Arch Cardiovasc Dis; 2020 Jan; 113(1):5-8. PubMed ID: 31917124
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
    Ait-Oufella H; Libby P; Tedgui A
    Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1510-1519. PubMed ID: 31294625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A perspective on targeting inflammation and cytokine actions in atherosclerosis.
    Chan YH; Ramji DP
    Future Med Chem; 2020 Apr; 12(7):613-626. PubMed ID: 32175772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
    Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
    Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammasomes as Potential Therapeutic Targets in Atherosclerotic Cardiovascular Disease.
    Wang P; Ma J; Zhang R
    Endocr Metab Immune Disord Drug Targets; 2022; 22(14):1378-1389. PubMed ID: 35392792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgE Contributes to Atherosclerosis and Obesity by Affecting Macrophage Polarization, Macrophage Protein Network, and Foam Cell Formation.
    Zhang X; Li J; Luo S; Wang M; Huang Q; Deng Z; de Febbo C; Daoui A; Liew PX; Sukhova GK; Metso J; Jauhiainen M; Shi GP; Guo J
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):597-610. PubMed ID: 31996021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
    Jones SA; Scheller J; Rose-John S
    J Clin Invest; 2011 Sep; 121(9):3375-83. PubMed ID: 21881215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis.
    Tumurkhuu G; Dagvadorj J; Porritt RA; Crother TR; Shimada K; Tarling EJ; Erbay E; Arditi M; Chen S
    Cell Metab; 2018 Sep; 28(3):432-448.e4. PubMed ID: 29937375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis.
    Yeh CF; Chen YH; Liu SF; Kao HL; Wu MS; Yang KC; Wu WK
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.
    McLaren JE; Michael DR; Ashlin TG; Ramji DP
    Prog Lipid Res; 2011 Oct; 50(4):331-47. PubMed ID: 21601592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.